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a b s t r a c t
Nitric oxide (NO)-derived metabolites including the anion nitrite can recycle back to NO and thus
complement NO formation independent of NO synthases. While nitrite is as a major vascular storage pool
and source of NO, little is known about drugs that increase tissue nitrite concentrations. This study
examined the effects of atorvastatin or sildenaﬁl, or the combination, on vascular nitrite concentrations
and on endothelial dysfunction in the 2 kidney-1 clip (2K1C) hypertension model. Sham-operated or
2K1C hypertensive rats were treated with vehicle, atorvastatin (50 mg/Kg), sildenaﬁl (45 mg/Kg), or both
for 8 weeks. Systolic blood pressure (SBP) was monitored weekly. Nitrite concentrations were assessed in
the aortas and in plasma samples by ozone-based reductive chemiluminescence assay. Aortic rings were
isolated to assess endothelium-dependent and independent relaxation. Aortic NADPH activity and ROS
production were evaluated by luminescence and dihydroethidium, respectively, and plasma TBARS levels
were measured. Aortic nitrotyrosine staining was evaluated to assess peroxynitrite formation. Atorvas-
tatin and sildenaﬁl, alone or combined, signiﬁcantly lowered SBP by approximately 40 mmHg.
Atorvastatin signiﬁcantly increased vascular nitrite levels by 70% in hypertensive rats, whereas sildenaﬁl
had no effects. Both drugs signiﬁcantly improved the vascular function, and decreased vascular NADPH
activity, ROS, and nitrotyrosine levels. Lower plasma TBARS concentrations were found with both
treatments. The combination of drugs showed no improved responses compared to each drug alone.
These ﬁndings show evidence that atorvastatin, but not sildenaﬁl, increases vascular NO stores, although
both drugs exert antioxidant effects, improve endothelial function, and lower blood pressure in 2K1C
hypertension.
& 2013 The Authors. Published by Elsevier B.V.
Introduction
Nitric oxide (NO) is a major player in normal cardiovascular
physiology [1] and its deﬁciency causes endothelial dysfunction, a
critical mechanism in the pathogenesis of cardiovascular diseases
including hypertension [2,3]. Oxidized NO forms the anions nitrite
(NO2) and nitrate (NO3), and it is now clear that NO-derived
metabolites can recycle back to NO through a nitrate–nitrite–NO
pathway that complements NO formation independent of NO
synthases [4,5]. Importantly, nitrite anions are now considered
as a major vascular storage pool and source of NO [6,7], and
therefore drugs that increase the vascular concentrations of nitrite
may promote therapeutic effects, particularly in disease conditions
associated with NO depletion [2]. However, very few studies have
examined how drugs that improve endothelial dysfunction affect
vascular nitrite levels, especially in hypertension. Examining this
possibility is very important because NO production from nitrite
occurs mostly in tissues [7] and therefore assessing tissue nitrite
levels may improve our understanding of how the nitrite–NO
pathway mediates critical functions [8].
In this study, we hypothesized that drugs activating the
NO-cyclic guanosine monophosphate (cGMP) pathway could
increase the vascular stores of NO (assessed as tissue nitrite
concentrations) and thus improve the vascular function in hyper-
tension. We examined how atorvastatin or sildenaﬁl, or the combi-
nation of both drugs, affect the vascular nitrite concentrations in the
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2 kidney-1 clip (2K1C) hypertension model. This model exhibits
many features of clinical hypertension including increased vascular
oxidative stress, impaired vascular NO activity, and endothelial
dysfunction [9–12]. While statins improve endothelial dysfunction
by mechanisms that reduce reactive oxygen species (ROS) forma-
tion and enhance NO activity [13,14], no previous study has
examined whether atorvastatin increases the vascular NO stores
in 2K1C hypertension. Moreover, while phosphodiesterase 5 inhibi-
tors (PDE5i) activate the NO-cGMP pathway by inhibiting cGMP
degradation, antioxidant mechanisms activated by these drugs may
reduce tissue ROS concentrations and therefore may improve
vascular NO bioavailability by preventing the reaction of NO with
ROS [15–17]. However, it is unknown whether sildenaﬁl improves
vascular NO stores and improves endothelial dysfunction in 2K1C
hypertension. The present study addresses the effects of both drugs
and the combination therapy, which could offer additive effects on
vascular nitrite levels and function [18–20].
Material and methods
Animals and treatments
This study was approved by the Institutional Animal Care and
Use Committee of the Faculty of Medicine of Ribeirao Preto,
University of Sao Paulo, and the animals were handled according
to the guiding principles published by the National Institutes of
Health. Male Wistar rats (180–200 g) were maintained on 12-h
light/dark cycle at 25 1C with free access to rat chow and water.
Surgical procedures and experimental protocols
2K1C hypertension was induced by clipping the left renal artery
with a silver clip (0.2 mm). Sham-operated rats underwent the
same surgical procedure (under general anesthesia with ketamine
100 mg/kg and xylazine 10 mg/kg i.p.), except for the placement of the
renal artery clip. Body weight and systolic blood pressure (SBP) were
assessed weekly. SBP were measured by tail-cuff plethysmography,
and the rats were considered hypertensive when SBP4160mmHg
two weeks after the surgery.
Animals were randomly assigned to one of eight groups: 2K1C
and Sham groups that received ethanol 2% (vehicle used to dilute
both drugs); 2K1C and Sham groups that received atorvastatin at
50 mg/kg per day [21]; 2K1C and Sham groups that received
sildenaﬁl at 45 mg/kg per day [22]; and 2K1C and Sham groups
that received the combination of atorvastatin 45 mg/kgþsildenaﬁl
50 mg/kg per day. The treatments were started two weeks after
2K1C hypertension was induced and maintained for additional
eight weeks. All treatments were given daily by oral gavage and
after 10 weeks of hypertension, the animals were killed by
decapitation and their thoracic aortas were isolated and cleaned
of connective tissue and fat. Arterial blood samples were centri-
fuged at 1000g for 10 min and plasma fractions were immediately
stored at 70 1C until used for biochemical measurements.
Determination of plasma and vascular nitrite concentrations
The plasma and aortic extracts were analyzed in duplicate for
their nitrite content using an ozone-based reductive chemilumi-
nescence assay as previously described [23,24]. The aortas were
homogenized in ice-cold phosphate buffer (pH 7.4; 500 μl) and
homogenates were kept on ice in the dark and used within 30 min
of preparation. Brieﬂy, to measure nitrite concentration, 50 μl of
plasma or 200 μl of aortic extracts samples were injected into a
solution of acidiﬁed triiodide, purging with nitrogen in line with a
gas phase chemiluminescence NO analyzer (Sievers Model 280 NO
analyzer, Boulder, CO, USA). Approximately 8 ml of triiodide
solution (2 g potassium iodide and 1.3 g iodine dissolved in
40 ml water with 140 ml acetic acid) was placed in the purge
vessel into which the samples were injected. The triiodide solution
reduces nitrites to NO gas, which is detected by the NO analyzer.
The data were analyzed using the software Origin Lab 6.1.
Vascular reactivity
The thoracic aortas were isolated and rings 4 mm in length were
cut and mounted for isometric tension recording. The rings were
placed in bath chambers (5 ml) for isolated organs containing
modiﬁed Krebs salt solution with the following composition
(mmol/L): NaCl 130, CaCl2 1.6, MgSO4 1.2, KH2PO4 1.2, KCl 4.7,
NaHCO3 14.9, glucose 5.5. This solution was maintained at 37 1C,
pH 7.4, and bubbled with 95% O2 and 5% CO2. The system was
connected to an isometric force displacement transducer (Letica
Scientiﬁc Instruments, Barcelona, Spain) and the responses were
recorded on a computer system using the Chart version 4.04,
PowerLab ADInstruments (2000) program. The aortic rings were
subjected to a tension of 1.5 g for a 60-min equilibration period and
were considered to have intact functional endothelium when acet-
ylcholine (103 mol/L) produced more than 80% relaxation, which
was calculated as a percentage of the contraction induced by
phenylephrine (107 mol/L). To assess endothelium-dependent and
endothelium-independent relaxation, aortic rings precontracted with
phenylephrine (104 mol/L) were used to construct cumulative
concentration–response curves to acetylcholine (1010–105 mol/L)
and to sodium nitroprusside (1010–105 mol/L) [25].
Assessment of vascular ROS formation, vascular NADPH activity, and
lipid peroxide levels in plasma
Dihydroethidium (DHE) was used to evaluate vascular produc-
tion of reactive oxygen species (ROS). Brieﬂy, aortic tissues were
embedded vertically in Tissue-teks and criostetized. The aortic
sections were incubated with DHE (10 μmol/L) as previously
described [26] and examined with ﬂuorescence microscopy (Leica
Imaging Systems Ltd., Cambridge, England). The images were
captured at x400 and the intensity of the red ﬂuorescent signal
was evaluated by using ImageJ Program (NIH – National Institute
of Health).
Vascular NADPH-dependent superoxide production was mea-
sured in aortic rings from all experimental groups as previously
described [26]. Aortic rings were transferred to luminescence vials
containing 1 mL of Krebs-HEPES buffer, pH 7.4. After equilibration
and background counts, a nonredox cycling concentration of
lucigenin (5 μmol/L) and NADPH (300 μmol/L) were automatically
added and the luminescence counts measured continuously for
15 min in a Berthold FB12 single tube luminometer at 37 1C.
Background signals from aortic rings were subtracted from the
NADPH-driven signals and the results were normalized for the dry
weight and reported as RLU/mg/min.
Plasma lipid peroxide levels were determined by measuring
thiobarbituric acid reactive substances (TBARS) using a ﬂuori-
metric method that requires excitation at 515 nm and emission
at 553 nm as previously described [27]. The lipoperoxide levels
were expressed in terms of malondialdehyde (MDA) (nmol/mL).
Immunohistochemistry assessment of vascular nytrotirosine levels
Vascular nitrotyrosine levels were measured in aortas ﬁxed in 4%
phosphate-buffered paraformaldehyde, pH 7.4, and embedded in
parafﬁn. Tissue sections (5 μm thick) were deparafﬁnized, washed
with phosphate buffer, and submitted to heat-induced antigen
retrieval, endogenous peroxidase inhibition, and non-speciﬁc antibody
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blocking. Subsequently, the sections were incubated overnight at 4 1C
with the anti-nitrotyrosine primary antibody (1:100; Millipore) and
with the secondary antibody (1:200; Millipore). Antigen was visua-
lized with a labelled streptavidin biotin peroxidase technique (Vectas-
tain ABC kit; Vector Laboratories Inc.) with 3,3′-diaminobenzidine
(DAB) substrate [28]. Sections were counterstained with haematoxylin,
and examined using light microscopy (Leica Imaging Systems Ltd.,
Cambridge, England) and the image was captured at x400. Immunor-
eactivity intensity was measured using the ImageJ Program.
Statistical analysis
The results are expressed as means7S.E.M. Comparisons
between groups were assessed by two-way or one way ANOVA
followed by the Tukey test using GraphPad Prism software.
A probability valueo0.05 was considered signiﬁcant.
Results
Effects of treatments on systolic blood pressure (SBP) and body
weight
The baseline SBP was similar in the eight experimental groups,
and no signiﬁcant changes were found in the Shamþvehicle and
in the Shamþtreatment groups (Fig. 1A). SBP increased progres-
sively in the 2K1CþVehicle group (ﬁnal SBP¼20074 mmHg).
The treatment of 2K1C rats with atorvastatin, sildenaﬁl, or both
drugs exerted similar antihypertensive effects (ﬁnal SBP¼14876,
15672, and 13874 mmHg, respectively; Fig. 1A; Po0.05). Simi-
lar body weight gain was found in the eight experimental groups
(Fig. 1B; P40.05).
Effects of drug treatments on aortic and plasma nitrite concentrations
To examine the effects of drug treatments on the vascular stores
of NO, nitrite concentrations were assessed in aortic and in plasma
samples. Treatment with atorvastatin signiﬁcantly increased nitrite
concentrations in the aortas from 2K1C hypertensive animals by
approximately 70% (Po0.05), whereas this statin only marginally
(P¼0.085) increased nitrite concentrations in Sham-operated ani-
mals (Fig. 2A). In contrast with atorvastatin, treatment with
sildenaﬁl did not affect aortic nitrite concentrations in both Sham-
operated and in 2K1C hypertensive rats (P40.05; Fig. 2A).
To further conﬁrm the effects of treatments on NO storage, we
measured nitrite concentrations in plasma samples. Interestingly,
the changes in plasma nitrite concentrations were similar to those
found in the aortic tissue. While atorvastatin treatment increased
plasma nitrite concentrations by approximately 70% to 110% in
2K1C and in Sham-operated animals, sildenaﬁl increased plasma
nitrite concentrations only in Sham-operated animals (all Po0.05;
Fig. 2B).
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Fig. 1. Systolic blood pressure (mmHg) measured by tail-cuff method (panel A) and body weight (panel B) in the eight experimental groups along 10 weeks of study
(n¼7–10/group). Data are shown as mean7S.E.M. nPo0.01 versus Sham Vehicle group; nnPo0.01 versus 2K1C Vehicle group.
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No signiﬁcant interactions were found between atorvastatin
and sildenaﬁl treatments with respect to aortic or plasma nitrite
concentrations (P40.05; Fig. 2A and B).
Effects of treatments on vascular function
To examine whether increased vascular NO storage as a result of
drug treatment would translate into improved vascular function, we
examined the vascular responses to acetylcholine. Fig. 3A shows
impaired endothelial cell-dependent responses to acetylcholine in
2K1C hypertensive rats as compared with the Sham-operated
groups, as revealed by a right shift in the concentration–dependent
responses and decreased maximum response to acetylcholine in
hypertensive rats (Po0.05; Fig. 3A). Treatment with atorvastatin or
sildenaﬁl, or both, restored the vascular responses to acetylcholine
(Po0.05; Fig. 3B).
No signiﬁcant changes were found in the aortic responses to
sodium nitroprusside when 2K1C hypertensive rats were com-
pared with Sham-operated controls, and drug treatments had no
effects on the responses to this NO-donor drug (P40.05; Fig. 3C).
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Fig. 2. Nitrite concentrations (mM; n¼7–9/group) in the aortas (panel A) and in plasma samples (mM; n¼4–5/group) from rats at the end of treatment. Nitrite concentrations
were assessed by reductive chemiluminescence. Data are shown as mean7S.E.M. nPo0.05 versus respective Vehicle group.
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Fig. 3. Endothelial cell-dependent vasorelaxation induced by acetylcholine (panels A and B) and endothelial cell-independent relaxation induced by sodium nitroprusside.
Rat aortic ring preparations were studied after precontraction with phenylephrine (107 M) (n¼6–10/group). Data are shown as mean7S.E.M. nPo0.05 versus Sham Vehicle
group (panel A); # Po0.05 versus 2K1C treated groups (panel B).
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No signiﬁcant interactions were found when both drug treat-
ment were combined (P40.05; Fig. 3A–C).
Effects of treatments on 2K1C-induced increases in oxidative stress
Treatment with atorvastatin or sildenaﬁl could contribute to
increased NO bioavailability by decreasing hypertension-induced
oxidative stress. To examine the possible antioxidant effects of
both drugs, we used three different methods. First, we used the
ﬂuorescent superoxide indicator DHE to study the effects of the
treatments on 2K1C hypertension-induced increases in ROS pro-
duction in aortic tissues. Fig. 4A and B shows higher vascular ROS
levels in 2K1C hypertensive rats compared with Sham-operated
groups (Po0.05). While drug treatments exerted no effects in
Sham-operated groups, both drugs abolished 2K1C-induced
increases in vascular ROS production (Po0.05; Fig. 4A and B).
To conﬁrm antioxidant effects exerted by both drugs, we mea-
sured the NADPH oxidase activity in the aortas from rats. This is
important because vascular ROS are produced in endothelial, adven-
titial, and vascular smooth muscle cells and derive primarily from
NADPH oxidase activity. Fig. 4C shows that hypertension was
associated with increased NADPH oxidase activity when compared
with Sham-operated groups, and both drugs signiﬁcantly decreased
NADPH oxidase activity in hypertensive rats (Po0.05).
To further validate the antioxidant effects found in vascular
tissue, we measured plasma lipid peroxide levels. Higher mal-
ondialdehyde (MDA) levels were found in 2K1CþVehicle group as
compared with the Sham-operated groups (Po0.05; Fig. 4D). Both
drug treatments were associated with lower MDA levels in 2K1C
hypertensive rats (Po0.05; Fig. 4D).
The combination of drugs did not improve the antioxidant
effects of each individual drug treatment (P40.05; Fig. 4A–D).
Effects of treatments on vascular nitrotyrosine levels
Diffusion-limited reaction between superoxide and NO results
in peroxinitrite formation [29], and this highly reactive molecule
increases tissue nitrotyrosine levels. Therefore, we examined
whether antioxidant effects exerted by atorvastatin or sildenaﬁl
could prevent hypertension-induced increases in vascular nitro-
tyrosine levels. While higher vascular nitrotyrosine levels were
found in 2K1C hypertensive rats (Po0.05), both drug treatments
attenuated this alteration (Fig. 5A and B; Po0.05). No further
attenuation was found when drug treatments were combined
(Fig. 5A and B; P40.05).
Discussion
This is the ﬁrst study to show that atorvastatin, but not
sildenaﬁl, increased vascular nitrite concentrations in hypertensive
rats. We demonstrated for the ﬁrst time that both drugs exerted
similar antioxidant and antihypertensive effects, and prevented
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Fig. 4. Effects of drug treatments on vascular oxidative stress. Panel A shows representative photomicrographs (x400) with red ﬂuorescence of DHE aortic samples from
hypertensive and Sham-operated rats. Panel B shows the quantiﬁcation of aortic ﬂuorescence (n¼8/group). Panel C shows NADPH-dependent superoxide production
measured as lucigenin chemiluminescence in the aortic rings (n¼6–8/group). Panel D shows lipid peroxide levels measured in plasma samples and expressed in terms of
MDA (n¼10/group). Data are shown as mean7S.E.M. nPo0.05 versus Sham Vehicle group; nnPo0.05 versus 2K1C Vehicle group. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article).
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2K1C hypertension-induced endothelial dysfunction. No signiﬁ-
cant additive effects were found when both drugs were combined.
Increased production of angiotensin II in 2K1C hypertension
activates NADPH oxidase, increases vascular ROS, and causes vascular
dysfunction [30], as we reported here. Both atorvastatin and silde-
naﬁl exerted antihypertensive effects in the 2K1C hypertension
model, and this effect was consistently associated with antioxidant
effects, as revealed by results obtained with three independent
assays to evaluate vascular and systemic oxidative stress. Further
conﬁrming these results, both drugs at least tended to lower vascular
nitrotyrosine levels in hypertensive rats. These results may explain
the improved vascular function in 2K1C hypertensive rats treated
with either atorvastatin or sildenaﬁl. Indeed, our ﬁndings support
previous studies showing similar effects of atorvastatin [21] in
spontaneously hypertensive rats (SHR). In agreement with our
ﬁndings, the authors showed that atorvastatin reduced systolic blood
pressure by approximately 20 mmHg and improved endothelial
dysfunction as a result of lower vascular ROS levels [21]. It is possible
that some quantitative differences in the antihypertensive effects
(40 mmHg decrease in SBP with atorvastatin in the present study
versus 20 mmHg in the previous study [21]) may reﬂect differences
in study design or animal model.
The responses we found with sildenaﬁl are similar to those
previously shown in rats with NO depletion-induced hypertension
[22] or in the SHR model [31]. The antihypertensive effects and the
prevention against endothelial dysfunction of 2K1C hypertension
with atorvastatin or sildenaﬁl probably resulted of antioxidant
mechanisms shared by both drugs. The increased ROS levels formed
in the vasculature from hypertensive animals react with NO gen-
erating peroxinitrite and reduce tissue NO activity [9]. Our results
suggest that this critical mechanismmay have been blunted by both
drugs, thus improving endothelial-dependent vascular responses
and lowering blood pressure. Together, our ﬁndings and those
previously reported strongly suggest that both atorvastatin and
sildenaﬁl exert signiﬁcant pleiotropic effects, independent of the
canonical mechanism explaining their in vivo effects.
Tissue and circulating nitrite levels have been widely measured in
experimental and clinical studies because nitrite plays important roles
in signaling and regulation of blood ﬂow [4,32,33]. In fact, low nitrite
levels indicate endothelial dysfunction and are associated with cardi-
ovascular risk factors [34]. Consistent with our results, circulating
nitrite levels are usually below 1 mM, whereas tissue concentrations
may achieve 10–20 mM [24,35]. The signiﬁcant differences between
circulating and tissue nitrite concentrations are very relevant because
there is evidence that nitrite conversion into NO occurs predominantly
in tissues [7], and therefore pharmacological approaches that increase
vascular nitrite concentrations may offer improved cardiovascular
protection.
Low vascular or plasma nitrite levels could indicate endothelial
dysfunction contributing to hypertension. However, we found similar
aortic or plasma nitrite concentrations in 2K1C hypertensive rats
compared to sham operated controls. While this ﬁnding could suggest
that the 2K1C hypertension model may not be the most appropriate
model to use since there was no reduction in vascular or plasma
nitrate levels, there are clear time-dependent pathophysiological
alterations in this hypertension model, with signiﬁcant activation of
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the renin-angiotensin system during the initial weeks [36], which is
apparently normalized in the following weeks [37]. Time-dependent
changes in nitrite concentrations in 2K1C hypertension may explain
the lack of signiﬁcant differences that we found with respect to nitrite
concentrations. Indeed, we have consistently found lower nitrite
[27,38], nitrate [38], and nitroso species [39] concentrations in 2K1C
hypertensive rats compared to controls after 4 weeks of 2K1C
hypertension, but not after 8 weeks of hypertension. While it might
have been more interesting to determine the effects of atorvastatin
and sildenaﬁl on nitrite levels at an earlier phase of 2K1C hyperten-
sion, we wanted to avoid this phase of transition from high to low
renin-angiotensin system activity [36,37]. Adding complexity to this
issue, aortic inducible NOS (iNOS) expression doubled after 8 weeks of
2K1C hypertension [25], and it is not clear how increased iNOS
expression may affect nitrite levels in 2K1C hypertension.
Interestingly, while both atorvastatin and sildenaﬁl exerted
antioxidant effects and improved endothelial dysfunction, we
found increased vascular and plasma nitrite levels only in animals
treated with atorvastatin. While this particular result could sug-
gest that increasing tissue nitrite levels is not relevant to improve
endothelial dysfunction or to lower blood pressure, we have not
compared long term effects of both drugs in this hypertension
model. For example, although we have not examined vascular
hypertrophy or remodeling in the present study, it is possible that
increased vascular nitrite levels translate into less vascular remo-
deling of hypertension, independent of drug-induced antihyper-
tensive effects. This suggestion is supported by recent ﬁndings
showing that nitrite promotes NO generation in vessels and in
smooth muscle cells, and decreases cell proliferation [40]. Further
studies are required to examine whether statin-induced increases
in vascular nitrite concentrations really attenuate vascular growth
in hypertension models and in patients. Moreover, both atorvas-
tatin and sildenaﬁl showed antioxidant effects, and therefore it is
probable that the increases in vascular nitrite concentrations do
not necessarily reﬂect antioxidant effects.
Previous studies reported that combining sildenaﬁl and atorvas-
tatin improves vascular responses more than each drug alone
[18–20]. While our present results do not support this suggestion,
it is possible that differences between animal models may explain
the lack of interaction reported here. While the doses used in the
present study were based on previous studies [21,22], it is possible
that maximum effects have been achieved with each drug, thus
preventing us to detect signiﬁcant interactions between treatments.
In conclusion, we demonstrate that atorvastatin and sildenaﬁl
exert antioxidant effects, improve endothelial function, and lower
blood pressure in 2K1C hypertension. While both drugs showed
similar effects, only atorvastatin increased vascular NO stores. This
effect may translate into improved long-term protective effects
against cardiovascular events in hypertension.
References
[1] S. Moncada, A. Higgs, The L-arginine-nitric oxide pathway, N. Engl. J. Med. 329
(1993) 2002–2012.
[2] G.D. Thomas, W. Zhang, R.G. Victor, Nitric oxide deﬁciency as a cause of clinical
hypertension: promising new drug targets for refractory hypertension, J. Am.
Med. Assoc. 285 (2001) 2055–2057.
[3] L. Ghiadoni, S. Taddei, A. Virdis, Hypertension and endothelial dysfunction:
therapeutic approach, Curr. Vasc. Pharmacol. 10 (2012) 42–60.
[4] M.T. Gladwin, A.N. Schechter, D.B. Kim-Shapiro, R.P. Patel, N. Hogg, S. Shiva,
R.O. Cannon 3rd, M. Kelm, D.A. Wink, M.G. Espey, E.H. Oldﬁeld, R.M. Pluta,
B.A. Freeman, J.R. Lancaster Jr., M. Feelisch, J.O. Lundberg, The emerging
biology of the nitrite anion, Nat. Chem. Biol. 1 (2005) 308–314.
[5] J.O. Lundberg, M.T. Gladwin, A. Ahluwalia, N. Benjamin, N.S. Bryan, A. Butler,
P. Cabrales, A. Fago, M. Feelisch, P.C. Ford, B.A. Freeman, M. Frenneaux,
J. Friedman, M. Kelm, C.G. Kevil, D.B. Kim-Shapiro, A.V. Kozlov, J.R. Lancaster
Jr, D.J. Lefer, K. McColl, K. McCurry, R.P. Patel, J. Petersson, T. Rassaf, V.P. Reutov,
G.B. Richter-Addo, A. Schechter, S. Shiva, K. Tsuchiya, E.E. van Faassen,
A.J. Webb, B.S. Zuckerbraun, J.L. Zweier, E. Weitzberg, Nitrate and nitrite in
biology, nutrition and therapeutics, Nat. Chem. Biol. 5 (2009) 865–869.
[6] K. Cosby, K.S. Partovi, J.H. Crawford, R.P. Patel, C.D. Reiter, S. Martyr, B.K. Yang,
M.A. Waclawiw, G. Zalos, X. Xu, K.T. Huang, H. Shields, D.B. Kim-Shapiro,
A.N. Schechter, R.O. Cannon 3rd, M.T. Gladwin, Nitrite reduction to nitric oxide
by deoxyhemoglobin vasodilates the human circulation, Nat. Med. 9 (2003)
1498–1505.
[7] H. Li, H. Cui, T.K. Kundu, W. Alzawahra, J.L. Zweier, Nitric oxide production
from nitrite occurs primarily in tissues not in the blood: critical role of
xanthine oxidase and aldehyde oxidase, J. Biol. Chem. 283 (2008)
17855–17863.
[8] S. Shiva, Nitrite: a physiological store of nitric oxide and modulator of
mitochondrial function, Redox Biol. 1 (2013) 40–44.
[9] R.M. Touyz, A.M. Briones, Reactive oxygen species and vascular biology:
implications in human hypertension, Hypertens. Res. 34 (2011) 5–14.
[10] H. Cai, K.K. Griendling, D.G. Harrison, The vascular NAD(P)H oxidases as
therapeutic targets in cardiovascular diseases, Trends Pharmacol. Sci. 24
(2003) 471–478.
[11] M.M. Castro, E. Rizzi, L. Figueiredo-Lopes, K. Fernandes, L.M. Bendhack,
D.L. Pitol, R.F. Gerlach, J.E. Tanus-Santos, Metalloproteinase inhibition amelio-
rates hypertension and prevents vascular dysfunction and remodeling in
renovascular hypertensive rats, Atherosclerosis 198 (2008) 320–331.
[12] M.M. Castro, E. Rizzi, G.J. Rodrigues, C.S. Ceron, L.M. Bendhack, R.F. Gerlach,
J.E. Tanus-Santos, Antioxidant treatment reduces matrix metalloproteinase-2-
induced vascular changes in renovascular hypertension, Free Radic. Biol. Med.
46 (2009) 1298–1307.
[13] M. Endres, U. Laufs, Effects of statins on endothelium and signaling mechanisms,
Stroke 35 (2004) 2708–2711.
[14] J. Davignon, Beneﬁcial cardiovascular pleiotropic effects of statins, Circulation
(2004)III39–III43.
[15] C. Vlachopoulos, N. Ioakeimidis, K. Rokkas, C. Stefanadis, Cardiovascular effects
of phosphodiesterase type 5 inhibitors, J. Sex. Med. 6 (2009) 658–674.
[16] C.A. Dias-Junior, D.C. Souza-Costa, T. Zerbini, J.B. da Rocha, R.F. Gerlach,
J.E. Tanus-Santos, The effect of sildenaﬁl on pulmonary embolism-induced
oxidative stress and pulmonary hypertension, Anesth. Analg. 101 (2005)
115–120.
[17] J.E. Tanus-Santos, Antioxidant effects of phosphodiesterase-5 inhibitors, Car-
diovasc. Res. 100 (2013) 170.
[18] Q.M. Wang, Y. Wei, Y. Zheng, C. Waeber, Efﬁcacy of combined atorvastatin and
sildenaﬁl in promoting recovery after ischemic stroke in mice, Am. J. Phys.
Med. Rehabil. 92 (2013) 143–150.
[19] M.M. Castro, E. Rizzi, R.R. Rascado, S. Nagassaki, L.M. Bendhack, J.E. Tanus-
Santos, Atorvastatin enhances sildenaﬁl-induced vasodilation through nitric
oxide-mediated mechanisms, Eur. J. Pharmacol. 498 (2004) 189–194.
[20] E.M. Neto-Neves, C.A. Dias-Junior, J.A. Uzuelli, R.P. Pereira, F. Spiller,
P.G. Czaikoski, J.E. Tanus-Santos, Sildenaﬁl improves the beneﬁcial hemody-
namic effects exerted by atorvastatin during acute pulmonary thromboembo-
lism, Eur. J. Pharmacol. 670 (2011) 554–560.
[21] S. Wassmann, U. Laufs, A.T. Baumer, K. Muller, K. Ahlbory, W. Linz, G. Itter,
R. Rosen, M. Bohm, G. Nickenig, HMG-CoA reductase inhibitors improve
endothelial dysfunction in normocholesterolemic hypertension via reduced
production of reactive oxygen species, Hypertension 37 (2001) 1450–1457.
[22] S.E. Ferreira-Melo, J.C. Yugar-Toledo, O.R. Coelho, I.M. De Luca, J.E. Tanus-
Santos, S. Hyslop, M.C. Irigoyen, H. Moreno Jr., Sildenaﬁl reduces cardiovas-
cular remodeling associated with hypertensive cardiomyopathy in NOS
inhibitor-treated rats, Eur. J. Pharmacol. 542 (2006) 141–147.
[23] M. Feelisch, T. Rassaf, S. Mnaimneh, N. Singh, N.S. Bryan, D. Jourd'Heuil, M. Kelm,
Concomitant S-, N-, and heme-nitros(yl)ation in biological tissues and ﬂuids:
implications for the fate of NO in vivo, FASEB J. 16 (2002) 1775–1785.
[24] N.S. Bryan, T. Rassaf, R.E. Maloney, C.M. Rodriguez, F. Saijo, J.R. Rodriguez,
M. Feelisch, Cellular targets and mechanisms of nitros(yl)ation: an insight into
their nature and kinetics in vivo, Proc. Natl. Acad. Sci. USA 101 (2004)
4308–4313.
[25] S.B. Cau, D.A. Guimaraes, E. Rizzi, C.S. Ceron, L.L. Souza, C.R. Tirapelli, R.F. Gerlach,
J.E. Tanus-Santos, Pyrrolidine dithiocarbamate down-regulates vascular matrix
metalloproteinases and ameliorates vascular dysfunction and remodelling in
renovascular hypertension, Br. J. Pharmacol. 164 (2011) 372–381.
[26] C.S. Ceron, M.M. Castro, E. Rizzi, M.F. Montenegro, V. Fontana, M.C. Salgado,
R.F. Gerlach, J.E. Tanus-Santos, Spironolactone and hydrochlorothiazide exert
antioxidant effects and reduce vascular matrix metalloproteinase-2 activity
and expression in a model of renovascular hypertension, Br. J. Pharmacol. 160
(2010) 77–87.
[27] M.F. Montenegro, L.C. Pinheiro, J.H. Amaral, D.M. Marcal, A.C. Palei, A.J. Costa-Filho,
J.E. Tanus-Santos, Antihypertensive and antioxidant effects of a single daily dose of
sodium nitrite in a model of renovascular hypertension, Naunyn Schmiedebergs
Arch. Pharmacol. 385 (2012) 509–517.
[28] C.M. Prado, M.A. Rossi, Circumferential wall tension due to hypertension plays
a pivotal role in aorta remodelling, Int. J. Exp. Pathol. 87 (2006) 425–436.
[29] D.G. Harrison, M.C. Gongora, T.J. Guzik, J. Widder, Oxidative stress and
hypertension, J. Am. Soc. Hypertens. 1 (2007) 30–44.
[30] O. Jung, J.G. Schreiber, H. Geiger, T. Pedrazzini, R. Busse, R.P. Brandes,
gp91phox-containing NADPH oxidase mediates endothelial dysfunction in
renovascular hypertension, Circulation 109 (2004) 1795–1801.
[31] K. Yaguas, R. Bautista, Y. Quiroz, A. Ferrebuz, H. Pons, M. Franco, N.D. Vaziri,
B. Rodriguez-Iturbe, Chronic sildenaﬁl treatment corrects endothelial dysfunc-
tion and improves hypertension, Am. J. Nephrol. 31 (2010) 283–291.
D.A. Guimarães et al. / Redox Biology 1 (2013) 578–585584
[32] M.T. Gladwin, N.J. Raat, S. Shiva, C. Dezfulian, N. Hogg, D.B. Kim-Shapiro,
R.P. Patel, Nitrite as a vascular endocrine nitric oxide reservoir that contributes
to hypoxic signaling, cytoprotection, and vasodilation, Am. J. Physiol. Heart
Circ. Physiol. 291 (2006) H2026–H2035.
[33] M.T. Gladwin, J.H. Crawford, R.P. Patel, The biochemistry of nitric oxide, nitrite,
and hemoglobin: role in blood ﬂow regulation, Free Radic. Biol. Med. 36
(2004) 707–717.
[34] P. Kleinbongard, A. Dejam, T. Lauer, T. Jax, S. Kerber, P. Gharini, J. Balzer,
R.B. Zotz, R.E. Scharf, R. Willers, A.N. Schechter, M. Feelisch, M. Kelm, Plasma
nitrite concentrations reﬂect the degree of endothelial dysfunction in humans,
Free Radic. Biol. Med. 40 (2006) 295–302.
[35] J.L. Zweier, H. Li, A. Samouilov, X. Liu, Mechanisms of nitrite reduction to nitric
oxide in the heart and vessel wall, Nitric Oxide 22 (2010) 83–90.
[36] A. Martins-Oliveira, M.M. Castro, D.M. Oliveira, E. Rizzi, C.S. Ceron,
D. Guimaraes, R.I. Reis, C.M. Costa-Neto, D.E. Casarini, A.A. Ribeiro,
R.F. Gerlach, J.E. Tanus-Santos, Contrasting effects of aliskiren versus losartan
on hypertensive vascular remodeling, Int. J. Cardiol. 167 (2013) 1199–1205.
[37] C.S. Ceron, E. Rizzi, D.A. Guimaraes, A. Martins-Oliveira, S.B. Cau, J. Ramos,
R.F. Gerlach, J.E. Tanus-Santos, Time course involvement of matrix metallo-
proteinases in the vascular alterations of renovascular hypertension, Matrix
Biol. 31 (2012) 261–270.
[38] M.F. Montenegro, J.H. Amaral, L.C. Pinheiro, E.K. Sakamoto, G.C. Ferreira,
R.I. Reis, D.M. Marcal, R.P. Pereira, J.E. Tanus-Santos, Sodium nitrite down-
regulates vascular NADPH oxidase and exerts antihypertensive effects in
hypertension, Free Radic. Biol. Med. 51 (2011) 144–152.
[39] M.F. Montenegro, E.M. Neto-Neves, C.A. Dias-Junior, C.S. Ceron, M.M. Castro,
V.A. Gomes, A. Kanashiro, J.E. Tanus-Santos, Quercetin restores plasma nitrite
and nitroso species levels in renovascular hypertension, Naunyn Schmiede-
bergs Arch. Pharmacol. 382 (2010) 293–301.
[40] M.J. Alef, R. Vallabhaneni, E. Carchman, S.M. Morris Jr, S. Shiva, Y. Wang,
E.E. Kelley, M.M. Tarpey, M.T. Gladwin, E. Tzeng, B.S. Zuckerbraun, N.O. Nitrite-
generated, circumvents dysregulated arginine/NOS signaling to protect
against intimal hyperplasia in Sprague-Dawley rats, J. Clin. Invest. 121
(2011) 1646–1656.
D.A. Guimarães et al. / Redox Biology 1 (2013) 578–585 585
